{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:57:06Z","timestamp":1777993026009,"version":"3.51.4"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are established first-line treatments for advanced non-small cell lung cancer (NSCLC) harboring common sensitizing EGFR mutations, such as exon 19 deletions (19del) and the exon 21 p.L858R point mutation. However, evidence regarding the efficacy of first-, second-, and third-generation EGFR-TKIs against uncommon EGFR exon 19 mutations, specifically p.L747P and p.L747S, remains limited, and the underlying mechanisms are not fully elucidated. This study aimed to evaluate the clinical efficacy of different-generation EGFR-TKIs in NSCLC patients harboring EGFR p.L747P or p.L747S mutations by integrating our institutional cases with published evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We identified patients with NSCLC harboring EGFR p.L747P or p.L747S mutations detected by next-generation sequencing (NGS) between 2020 and 2025 and retrospectively collected their clinical data. A literature review was conducted to identify and integrate relevant published case data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among seven treated stage IV NSCLC patients with the p.L747P mutation, two who received second-generation EGFR-TKIs as first-line therapy had an objective response rate (ORR) of 0% and experienced rapid disease progression. In contrast, six patients received third-generation EGFR-TKIs as first- or second-line therapy, with two achieving stable disease (SD) and one achieving partial response (PR), with a substantially longer progression-free survival (PFS) of 12 to 40 months. Separately, six patients were found to harbor the p.L747S mutation concomitantly with a common TKI-sensitive mutation, none of whom had received prior EGFR-TKI therapy. Of these, two patients were treated with a third-generation TKI: 1 achieved SD and the other achieved partial response (PR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This integrated retrospective analysis suggests that third-generation EGFR-TKIs may provide disease control (PR\/SD) and prolonged PFS in a subset of NSCLC patients harboring uncommon EGFR p.L747P or p.L747S mutations, particularly those with co-existing sensitizing mutations or central nervous system metastases (CNS).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1717191","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:25:48Z","timestamp":1769491548000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations"],"prefix":"10.3389","volume":"16","author":[{"given":"Qiongxia","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhujun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wengeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bojiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41698-021-00170-7","article-title":"Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity","volume":"5","author":"Yoshizawa","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00607.x","article-title":"Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer","volume":"98","author":"Mitsudomi","year":"2007","journal-title":"Cancer Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant\u00a0non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-08-1455","article-title":"Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib","volume":"14","author":"Costa","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70393-x","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12637","article-title":"Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report","volume":"9","author":"Huang","year":"2018","journal-title":"Thorac Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604068","article-title":"\u2018Classical\u2019 but not \u2018other\u2019 mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer","volume":"97","author":"Pallis","year":"2007","journal-title":"Br J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-018-0460-2","article-title":"Large-scale EGFR mutation testing in clinical practice: analysis of a series of 18,920 non-small cell lung cancer cases","volume":"25","author":"Evans","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.843299","article-title":"The lifted veil of uncommon EGFR mutation p.L747P in non-small cell lung cancer: molecular feature and targeting sensitivity to tyrosine kinase inhibitors","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-2361","article-title":"EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma","volume":"18","author":"He","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.05.019","article-title":"Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations","volume":"133","author":"Liang","year":"2019","journal-title":"Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"E802","DOI":"10.21037\/jtd.2018.12.26","article-title":"EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report","volume":"10","author":"Zhou","year":"2018","journal-title":"J Thorac Dis"},{"key":"B20","article-title":"EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma","volume":"8","author":"Yu","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2016.05.95","article-title":"Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report","volume":"8","author":"Wang","year":"2016","journal-title":"J Thorac Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15502","article-title":"A rare presentation of a non-asian female with metastatic non-small-cell lung cancer harboring EGFR L747P mutation with clinical response to multi-targeted epigenetic and EGFR inhibition","volume":"42","author":"Messeha","year":"2022","journal-title":"Anticancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.863771","article-title":"Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_433_22","article-title":"Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation","volume":"18","author":"Li","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.lungcan.2020.09.017","article-title":"A rare EGFR mutation L747P conferred therapeutic efficacy to both gefitinib and osimertinib: A case report","volume":"150","author":"Huang","year":"2020","journal-title":"Lung Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100291","article-title":"Systemic and intracranial efficacy of osimertinib in EGFR L747P-mutant NSCLC: case report","volume":"3","author":"Gerber","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31825ccae8","article-title":"A novel EGFR mutation in exon 19 showed stable disease after TKI treatment","volume":"7","author":"van der Wekken","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3892\/ol.2024.14634","article-title":"Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report","volume":"28","author":"Luo","year":"2024","journal-title":"Oncol Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.02.034","article-title":"Clinical efficacy of osimertinib in a patient presenting a double EGFR L747S and G719C mutation","volume":"14","author":"Grolleau","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.03.034","article-title":"Response to erlotinib in a patient with compound EGFR L747S and exon 19 deletion","volume":"13","author":"Swami","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.010","article-title":"A case treated with Crizotinib after secondary MET amplification of A double Rare L747S and G719S EGFR mutation Pulmonary Sarcomatoid Carcinoma","volume":"31","author":"He","year":"2020","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.14.9039","article-title":"Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations","volume":"26","author":"Costa","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1705","article-title":"Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-na\u00efve patient: A report of three cases","volume":"7","author":"Yamaguchi","year":"2014","journal-title":"Oncol Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0000000000000538","article-title":"Uncommon EGFR exon 19 mutations confer gefitinib resistance in advanced lung adenocarcinoma","volume":"10","author":"Coco","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-0780","article-title":"The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma","volume":"25","author":"Truini","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cllc.2020.04.011","article-title":"Clinical activity of afatinib in patients with non-small-cell lung cancer harboring uncommon EGFR mutations: A spanish retrospective multicenter study","volume":"21","author":"Moran","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11237","article-title":"Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing","volume":"7","author":"Jin","year":"2016","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3978\/j.issn.2218-6751.2014.11.06","article-title":"Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review","volume":"4","author":"Stewart","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040315","article-title":"BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with\u00a0oncogenic EGFR mutations","volume":"4","author":"Costa","year":"2007","journal-title":"PLoS Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12885-017-3263-z","article-title":"Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A","volume":"17","author":"Chiba","year":"2017","journal-title":"BMC Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.04.016","article-title":"Uncommon EGFR mutations in advanced non-small cell lung cancer","volume":"109","author":"O\u2019Kane","year":"2017","journal-title":"Lung Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cca.2013.11.014","article-title":"Efficiency of the Therascreen\u00ae RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas","volume":"429","author":"Vall\u00e9e","year":"2014","journal-title":"Clin Chim Acta"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0288","article-title":"Picoliter-droplet digital polymerase chain reaction-based analysis of cell-free plasma DNA to assess EGFR mutations in lung adenocarcinoma that confer resistance to tyrosine-kinase inhibitors","volume":"21","author":"Seki","year":"2016","journal-title":"Oncologist"},{"key":"B44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/jclinpath-2018-205386","article-title":"Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples","volume":"72","author":"Pepe","year":"2019","journal-title":"J Clin Pathol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/cyt.12265","article-title":"Challenges and opportunities of next-generation sequencing: a cytopathologist\u2019s perspective","volume":"26","author":"Vigliar","year":"2015","journal-title":"Cytopathology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1717191\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:25:49Z","timestamp":1769491549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1717191\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":45,"alternative-id":["10.3389\/fonc.2026.1717191"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1717191","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"article-number":"1717191"}}